The RESTORE Act (SB 1882) would direct the Department of Health and Human Services to expand research, data collection, reporting, and training related to reproductive health conditions and infertility. The bill focuses on conditions such as endometriosis, adenomyosis, polycystic ovary syndrome, uterine fibroids, blocked fallopian tubes, hormone imbalances, and male-factor infertility. It also promotes what the bill calls “restorative reproductive medicine” and “fertility awareness-based methods,” and it requires federal agencies to study access to those approaches, their coverage under public and private health plans, and their inclusion in federal surveys and training programs.
The bill would also affect federal health program administration and reimbursement. It would amend Title X eligibility to allow entities primarily engaged in restorative reproductive medicine or related training to qualify for grants or contracts, and it would direct HHS to update medical coding and reimbursement systems to better classify and pay for infertility-related diagnostics, surgeries, education, and care coordination. In addition, it would require HHS to expand research across multiple agencies, issue recurring reports, and consider adding new questions to the National Survey of Family Growth about reproductive health conditions and fertility-awareness practices.
A notable feature of the bill is its provider conscience protection. It would prohibit the federal government and recipients of federal funds, including state and local governments, from penalizing health care providers who decline to participate in assisted reproductive technology, including IVF-related services, when doing so conflicts with sincerely held religious beliefs or moral convictions. This provision would create a federal nondiscrimination rule for providers who opt out of assisted reproductive technology participation.
The general sentiment reflected in the bill text is strongly supportive of expanding attention to infertility, reproductive health conditions, and alternative diagnostic and treatment approaches. The findings emphasize delayed diagnosis, unmet care needs, and the value of earlier intervention, education, and research. Because there are no committee transcripts or votes provided, there is no recorded legislative debate or roll-call sentiment in the available context.
The main points of contention likely center on the bill’s treatment of assisted reproductive technology and its preference for restorative reproductive medicine and fertility-awareness methods. Supporters would likely view the bill as expanding options, research, and access to care, while critics may see it as elevating less-established approaches, potentially affecting IVF access, federal program standards, and reimbursement policy. The conscience-protection language for providers and the Title X and training provisions are the most likely areas of policy dispute.
SB 1882 would create new federal reporting, research, training, and reimbursement directives affecting HHS, CDC, NIH, AHRQ, ARPA-H, Title X, and the National Survey of Family Growth. It would not directly rewrite state law, but it could influence state and local health programs that receive federal funds by imposing nondiscrimination rules for providers who decline assisted reproductive technology and by shaping federal standards for infertility care, coding, and grant eligibility. The bill would also affect patients, clinicians, researchers, and federally funded health entities by expanding attention to reproductive health conditions and restorative reproductive medicine.
The bill’s text reflects a positive, expansion-oriented posture toward reproductive health research and infertility care, with repeated findings that current diagnosis and treatment are insufficient. The available context includes no committee transcript and no votes, so there is no recorded opposition or support from debate or floor action. Based on the bill language alone, the measure appears to be framed as a health-access and research bill, though it also contains policy choices that could generate partisan or ideological disagreement.
The most likely contention is over the bill’s preference for “restorative reproductive medicine” and fertility-awareness-based methods versus assisted reproductive technology such as IVF. Supporters are likely to argue that the bill broadens care options, improves diagnosis, and supports patients with infertility and reproductive disorders. Critics may object that it elevates a particular medical philosophy, could divert attention or funding from established fertility treatments, and may complicate access to assisted reproductive technology. The provider conscience clause, Title X eligibility changes, and required training/coding updates are additional flashpoints because they could affect service delivery, reimbursement, and federal program administration.